SMARCA2 inhibitors (Ryvu Therapeutics/Maria Sklodowska Curie Memorial Cancer Center)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameSMARCA2 inhibitors (Ryvu Therapeutics/Maria Sklodowska Curie Memorial Cancer Center)
Drug Alias NameSMARCA2/4 inhibitors (RyvuTherapeutics)SMARCA2 inhibitors (Selvita/Maria Sklodowska Curie Memorial Cancer Center)RVU-5363
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSMARCA4 inhibitorsProbable global transcription activator SNF2L2 inhibitors
TargetsProbable global transcription activator SNF2L2Transcription activator BRG1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPoland
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRyvu Therapeutics SaMaria Sklodowska-Curie Memorial Cancer Center
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A